Clinical Trial Update: Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating thiotepa in combination with pirtobrutinib and sintilimab for frail or relapsed/refractory primary or secondary cent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Sintilimab (sintilimab)
• THIOTEPA (THIOTEPA)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Pirtobrutinib, Sintilimab | Phase 2 | Status: RECRUITING